Highlights

  • Ramsay Health Care (ASX:RHC) reported FY26 customer revenue of A$18.58 billion.
  • Underlying FY26 EBIT reached A$1.16 billion, up 11.5% on a reported basis.
  • FY26 underlying NPAT after non-controlling interests was A$364.1 million.
  • A proposed Ramsay Santé separation remains subject to shareholder approval in November 2026.

Ramsay Health Care operates hospitals, day surgeries, clinics and related health services, including mental health, rehabilitation and care delivered outside hospitals. Its FY26 reporting outlined changes in Australian hospital activity, UK operations and the proposed separation of its European subsidiary, Ramsay Santé. On 20 October 2026, Ramsay Health Care Limited (ASX:RHC) was quoted at AUD 53.93, down 1.95% for the trading session. The market movement is not attributed to the August results announcement.

Company Business

Ramsay Health Care (ASX:RHC) provides hospital and clinical services through its Australian operations, its Ramsay UK hospital business, Elysium Healthcare and its controlling interest in Ramsay Santé. Australian facilities cover acute treatment, surgical procedures, mental health, rehabilitation and allied health. The UK businesses include hospitals and specialist mental health facilities. Ramsay Santé operates healthcare facilities in continental Europe, giving the consolidated group exposure to different hospital funding systems and labour markets.

The Australian business is central to the company’s operational transformation. Management has identified higher-acuity care, theatre utilisation, revenue indexation and operating expenses as priorities. Its research network also supports clinical trials across Australian sites, with the company reporting 22 participating sites in FY26.

Recent Development

In August 2026, Ramsay Health Care (ASX:RHC) released results for the year ended 30 June 2026. Australian hospital admissions increased 3.3%, excluding facilities returned to public operation, while theatre utilisation improved by approximately 90 basis points. Australian underlying EBIT grew 11.2% to A$639.8 million. The company reported a net A$26 million adverse effect from the revised funding mechanism at Joondalup Health Campus, partially offset through operating measures.

The group also advanced plans to distribute its Ramsay Santé shareholding to Ramsay shareholders in specie. The proposed separation remains conditional on approvals, including a shareholder vote scheduled for November 2026. Until approval and implementation, the transaction should be treated as a proposal rather than a completed restructuring.

Financial Performance and Sector Context

FY26 revenue from contracts with customers totalled A$18,577.8 million, compared with A$17,673.8 million in FY25, a 5.1% increase in reported currency and 4.2% at constant currency. Group underlying EBIT was A$1,162.2 million versus A$1,042.6 million, rising 11.5% on a reported basis. Underlying net profit after tax attributable after non-controlling interests increased to A$364.1 million from A$305.3 million; the constant-currency increase was 22.9%.

Reported net profit after tax attributable to owners of the parent reached A$329.2 million, compared with A$24.0 million in FY25. These statutory and underlying measures differ because the latter excludes designated non-recurring items. Ramsay Health Care (ASX:RHC) determined a fully franked final dividend of 48.5 cents per share, taking its FY26 total to 91.0 cents per share.

In the UK, Ramsay hospitals reported 10.3% constant-currency underlying EBIT growth despite an 8% reduction in NHS activity. Elysium recorded 43.5% constant-currency EBIT growth following site optimisation and expense initiatives. Ramsay Santé faced French hospital funding pressures, including insufficient tariff indexation relative to costs. These dynamics illustrate how reimbursement arrangements, treatment complexity and staffing expenses shape healthcare operating margins.

Risks to Consider

Ramsay Health Care (ASX:RHC) faces exposure to clinical staffing costs, reimbursement negotiations, hospital capacity utilisation and changes in public funding. The Joondalup funding adjustment illustrates contractual sensitivity. UK NHS volumes and demand for specialist mental health services may vary. The proposed Ramsay Santé distribution also involves shareholder and regulatory approvals, associated costs and potential changes to the group’s reporting structure.

What to Watch Next

Shareholders can monitor the proposed Ramsay Santé demerger vote, scheduled for 24 November 2026 alongside the annual general meeting. For FY27, management outlined Funding Group capital expenditure guidance of A$480 million to A$520 million and net financing expenses of A$280 million to A$300 million, including lease costs. These are company guidance figures rather than realised outcomes. Operational updates on Australian hospital utilisation, UK volumes and Elysium’s restructuring remain relevant.

Key Insights

Ramsay Health Care (ASX:RHC) ended FY26 with higher revenue and underlying earnings, alongside changes to its hospital portfolio and operating model. Australia delivered increased admissions and underlying EBIT, while the UK businesses reported improved earnings under mixed demand conditions. The next material disclosures concern shareholder consideration of Ramsay Santé, FY27 spending and the translation of operating initiatives into reported results.